What were Tatva Chintan Pharma Chem Ltd's latest quarterly results?
Tatva Chintan Pharma Chem Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +900.0%
- Revenue Growth YoY: +24.1%
- Operating Margin: 21.0%
Tatva Chintan Pharma Chem Ltd (Speciality Chemicals) — fundamental analysis, earnings data, and key metrics. PE: 67.1. ROE: 5.5%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Tatva Chintan Pharma Chem Ltd's latest quarterly results (Mar 2026) show
Tatva Chintan Pharma Chem Ltd's current PE ratio is 67.1x.
Tatva Chintan Pharma Chem Ltd's price-to-book ratio is 3.6x.
Tatva Chintan Pharma Chem Ltd's fundamental strength based on key financial ratios
Tatva Chintan Pharma Chem Ltd has a debt-to-equity ratio of N/A.
Tatva Chintan Pharma Chem Ltd's return ratios over recent years
Tatva Chintan Pharma Chem Ltd's operating cash flow is positive (FY2026).
Tatva Chintan Pharma Chem Ltd's current dividend yield is 0.08%.
Tatva Chintan Pharma Chem Ltd's shareholding pattern (Mar 2026)
Tatva Chintan Pharma Chem Ltd's promoter holding has remained stable recently.
Tatva Chintan Pharma Chem Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Tatva Chintan Pharma Chem Ltd may be worth studying
Tatva Chintan Pharma Chem Ltd investment thesis summary:
Tatva Chintan Pharma Chem Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.